title: Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.
abstract: Auto-SCT has been shown to be a potentially curative treatment for a variety of hematological malignancies. Auto-SCT is dependent on the successful mobilization and collection of hematopoietic stem cells to ensure engraftment. The inability to mobilize sufficient number of hematopoietic stem cells using standard cytokine-assisted mobilization strategies excludes eligible patients from potentially curative auto-SCT. Plerixafor (AMD3100; Mozobil), a novel bicyclam antagonist of the SDF-1alpha/CXCR4 complex, has been reported previously to augment PBSC mobilization in patients undergoing their first planned stem cell mobilization and collection attempt. In our experience, 17 of 20 patients otherwise eligible for auto-SCT who failed previous mobilization attempts had successful mobilization of CD34(+) hematopoietic stem cells with one apheresis procedure, and an additional patient required two aphereses procedures, when treated with the combination of plerixafor and G-CSF on a compassionate use protocol available at our institution.
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Northwest Marrow Transplant Program, Center for Hematological Malignancies, Oregon Health and Science University, Portland, OR 97239, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Fowler
authors.forename: A
authors.initials: A
authors.lastname: Dunn
authors.forename: B
authors.initials: B
authors.lastname: Hayes-Lattin
authors.forename: K
authors.initials: K
authors.lastname: Hansen
authors.forename: L
authors.initials: L
authors.lastname: Hansen
authors.forename: K
authors.initials: K
authors.lastname: Lanier
authors.forename: V
authors.initials: V
authors.lastname: Nelson
authors.forename: T
authors.initials: T
authors.lastname: Kovacsovics
authors.forename: J
authors.initials: J
authors.lastname: Leis
authors.forename: G
authors.initials: G
authors.lastname: Calandra
authors.forename: R T
authors.initials: RT
authors.lastname: Maziarz
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000096:biosynthesis; D001596:Benzylamines; D000080027:Cyclams; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006571:Heterocyclic Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C088327:plerixafor